Investor Relations

Sonoma Keeps You Informed

Sign up for email alerts to receive Sonoma updates including press releases, filings and special announcements straight to your inbox.

We're sorry, but this form has spam protection that requires JavaScript to be enabled to work correctly. If you'd like to contact us via this form, please enable scripts in your browser and reload the page.

First Name

Last Name

Email Address

Contact Type:

Sign me up for:

All Press Releases

All SEC Filings

10-K & 10-Q Reports

Current Reports

Insider Transactions

Proxy Information

Sonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn® Disinfectant & Sanitizer Has Received Approval to Be Entered Into the Australian Register of Therapeutic Goods (ARTG) for use against COVID-19

May 28, 2020

View All News

Q3 2020

Quarter Ended Dec 31, 2019

Earnings Release

PDF HTML

10-Q

PDF HTML

XBRL

ZIP XLS HTML

Latest Annual Filing

Fiscal Year Ended Mar 31, 2019

View Filing

Stock Information

Sonoma Pharmaceuticals is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The company's products, which are sold throughout the world, have improved outcomes for more than ten million patients globally by reducing infection, itch, pain, scarring and harmful inflammatory responses. Sonoma’s headquarters are in Petaluma, California, with manufacturing operations in both the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands.

Investor Contact Information

Company

Sonoma Pharmaceuticals, Inc.
1129 North McDowell Blvd.
Petaluma, CA 94954